Systemic Lupus Erythematosus is Not Necessarily a Contraindication to Adjuvant Breast Radiation Therapy.

Author: LongKaren, MartellKevin, OlivottoIvo A, SolisAlexa

Paper Details 
Original Abstract of the Article :
A 41-year-old woman presented with pT4dN1aM0, right-sided, inflammatory breast cancer. She had a co-morbid diagnosis of systemic lupus erythematosus (SLE) at the age of 20 and was found to have significant kidney involvement (lupus-associated nephritis) at the age of 28. She went on to receive six c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334888/

データ提供:米国国立医学図書館(NLM)

Systemic Lupus Erythematosus: A Case of Adjuvant Breast Radiation Therapy

Systemic lupus erythematosus (SLE), an autoimmune disorder, can complicate the management of other medical conditions, including cancer. This study, like a camel navigating a challenging sandstorm, presents a case of a woman with SLE who received adjuvant breast radiation therapy (RT) after undergoing surgery for inflammatory breast cancer. The study highlights the potential for managing RT in patients with SLE, despite the potential for increased side effects.

Adjuvant RT for Breast Cancer: A Case of Careful Management

The study describes a 41-year-old woman with SLE who successfully received adjuvant RT for breast cancer. The patient tolerated the therapy well, experiencing only grade three acute dermatitis, with no other significant side effects. This case demonstrates that, with careful planning and monitoring, adjuvant RT can be safely administered to patients with SLE who require this treatment modality.

SLE and Cancer Treatment: A Complex Interplay

This case report underscores the importance of individualized treatment approaches for patients with complex co-morbidities. The findings suggest that, with careful consideration of the risks and benefits, adjuvant RT can be a viable option for patients with SLE who have a high risk of breast cancer recurrence.

Dr.Camel's Conclusion

The desert of autoimmune disorders is vast and often unpredictable, but with careful planning and patient-centered care, we can find pathways for successful treatment. This case report highlights the potential for managing adjuvant RT in patients with SLE, offering hope for individuals facing the challenges of both autoimmune disease and cancer.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

30656087

DOI: Digital Object Identifier

PMC6334888

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.